Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
BOSTON, March 01, 2016 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, Chief Executive Officer of Zafgen, will present at the upcoming Cowen & Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016 at 10:40 a.m. ET.
A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
